Thrive Earlier Detection Secures $110 Million Series A Financing to Integrate Early Cancer Detection into Routine Healthcare

VCBeat (WeChat Official Account: vcbeat) learned from foreign media that on May 30, U.S. local time, medical technology company Thrive Earlier Detection completed a $110 million Series A financing round. The funds from this round will be used to support the company’s development of an early cancer diagnostic system.

Reportedly, this round of financing was led by Third Rock Ventures, with participation from Section 32, Casdin Capital, Biomatics Capital Partners, BlueCross BlueShield Venture Partners, Camden Partners, and others.

Thrive Earlier Detection, headquartered in Massachusetts, USA, is a medical technology company dedicated to advancing cancer detection systems to help cancer patients recover their health.

Cancer treatment has long been a focal point in the healthcare industry. The difficulty in treating cancer stems not only from its diverse types, rapid cellular malignant transformation, and widespread involvement across various tissues, but also from the fact that most cancers are asymptomatic in their early stages. By the time patients seek medical attention due to severe health issues, vital organs or tissues in the majority of cases have already undergone malignant transformation or necrosis.

Currently, the healthcare industry is gradually shifting its focus toward cancer prevention. Thrive Earlier Detection Corp. is committed to integrating cancer prevention into routine medical services, aiming to diagnose conditions during the latent phase of cancer and initiate timely treatment to help patients recover. The company has studied cancer markers that are commonly present in cancer patients and adopted them as diagnostic criteria. When instruments detect abnormal levels of these markers in the human body, a rigorous diagnosis of potentially malignant tissues is conducted to prevent disease progression.

Third Rock Ventures, founded in 2007 and headquartered in Massachusetts, USA, is a venture capital firm focused on investing in the early and late-stage development of startups in the life sciences sector, having completed 97 investments to date.

Section 32, a California-based venture capital fund founded in 2017 by Bill Maris, the founder of Google Ventures, is headquartered in the United States. Section 32 primarily invests in startups in the fields of technology, biotechnology, healthcare, and life sciences.

Casdin Capital is an investment firm focused on the life sciences and healthcare industries. Founded in 2011 and headquartered in New York, USA, the company primarily invests in enterprises during their early-stage and late-stage development phases. To date, Casdin Capital has made 37 investments, predominantly in the biotechnology sector.

Biomatics Capital Partners is a Seattle-based venture capital firm focused on healthcare and life sciences. The firm manages a $200 million fund, specializing in early-stage investments in startups within the genomics and digital health sectors.

BlueCross BlueShield Venture Partners, established in 2016 and headquartered in Illinois, USA, is a venture capital firm focused on investing in companies during their early and growth stages.

Camden Partners is a private equity firm headquartered in Maryland, USA. Founded in 1995, it primarily provides growth capital to lower-middle-market companies in the education, healthcare, and technology-enabled business services sectors.

(Compiled by Liu Yujing)